查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602742

心绞痛治疗药物市场：按类型、药物、给药途径、分销管道和最终用户分类 - 全球预测 2025-2030

Angina Pectoris Drugs Market by Type (Prinzmetal Angina, Stable Angina, Unstable Angina), Drugs (Anti-Ischemic Agents, Antihypertensive Agents, Antiplatelet Agents), Route of Administration, Distribution Channel, End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年心绞痛治疗市场价值为11.4亿美元，预计到2024年将达到12亿美元，复合年增长率为5.39%，到2030年预计将达到16.5亿美元。

心绞痛药物的范围包括治疗和管理与心臟供血不足引起的胸痛相关的症状。此类别包括硝酸盐、 β阻断剂、钙通道阻断剂和抗血小板药物等药物，这些药物对于缓解心绞痛症状和预防心臟病发作至关重要。全球心血管疾病的流行和老年人口的不断增长强调了对这些药物的需求，这使得它们在慢性病护理管理中至关重要。它的用途不仅仅是缓解症状，对于改善患者的生活品质和降低主要心血管事件的发生率至关重要。主要的最终用途市场包括医院、诊所和零售药房，由于医疗保健基础设施和意识的不断增强，新兴市场的使用量不断增加。

主要市场统计
基准年[2023] 11.4亿美元
预测年份 [2024] 12亿美元
预测年份 [2030] 16.5亿美元
复合年增长率（%） 5.39%

市场开拓和个人化医疗的进步以及医疗保健支出的增加是市场成长的关键驱动力。新的商机在于在持续研究和药物创新的推动下，开发针对冠状动脉疾病特定途径的新型疗法。对预防性医疗保健和生活方式改善的日益关注为市场渗透提供了进一步的机会。然而，成长受到严格的法规环境、开发新药的高成本以及导致患者违规的潜在副作用的限制。

主要挑战包括因专利到期而面临的学名药竞争，以及在低收入市场中平衡有效性和价格的需要。基因治疗、组合药物开发以及利用人工智慧预测患者反应和优化配方等领域的创新可能会取得进展。透过了解复杂的患者需求并投资于研发，我们可以取得突破。透过策略伙伴关係关係和本地市场渗透积极主动地拓展市场可以提高可及性。心绞痛治疗市场充满活力，在临床创新的推动下具有巨大的成长潜力，但必须克服监管和经济挑战才能充分实现这一前景。

市场动态：快速发展的心绞痛治疗市场的关键市场洞察

供需的动态交互作用正在改变心绞痛药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 由于心臟相关疾病的增加，文明病的负担增加
    • 新药物输送系统的增加
    • 政府支持加强心血管疾病防治
  • 市场限制因素
    • 对特定药物类别相关副作用的担忧
  • 市场机会
    • 个人化心血管照护的技术进步
    • 药品核准和临床研究快速成长
  • 市场挑战
    • 缺乏技术精湛、经验丰富的专业人员

波特五力：驾驭心绞痛药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对心绞痛治疗市场的影响

外部宏观环境因素在塑造心绞痛治疗药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解心绞痛治疗药物市场的竞争状况

对心绞痛治疗药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵心绞痛治疗市场供应商的绩效评估

FPNV 定位矩阵是评估心绞痛治疗药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘心绞痛治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对心绞痛治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 与文明病负担增加以及与心臟相关的疾病增加
      • 增强新的药物传输系统
      • 政府支持加强心血管疾病防治
    • 抑制因素
      • 对特定药物类别相关副作用的担忧
    • 机会
      • 个性化心血管医学的技术进步
      • 增加药物核准和临床研究
    • 任务
      • 缺乏技术精湛、经验丰富的专业人员
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章心绞痛治疗药物市场：依类型

  • 变异型心绞痛
  • 稳定型心绞痛
  • 不稳定型心绞痛

第7章：以市场药品分类的心绞痛治疗药物

  • 抗缺血剂
  • 抗高血压药
  • 抗血小板药
  • β受体阻断剂
  • 钙离子通道阻断剂
  • 硝酸盐
  • 他汀类药物

第八章 心绞痛治疗药物市场：依给药途径

  • 口服
  • 胃肠外的
  • 经皮

第九章心绞痛治疗药物市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第 10 章 心绞痛治疗药物市场：依最终使用者分类

  • 居家护理
  • 医院
  • 专科诊所

第十一章美洲心绞痛药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第12章：亚太心绞痛药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第13章：欧洲、中东和非洲心绞痛治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Alembic Pharmaceuticals Limited
  • Alkem Laboratories Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Centurion Remedies Private Limited
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Intas Pharmaceuticals Ltd.
  • Ipca Laboratories Ltd.
  • Lupin Ltd.
  • Macleods Pharmaceuticals Pvt Ltd.
  • Mankind Pharma
  • Merck & Co. Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi-Aventis Groupe SA
  • Sumitomo Corporation
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
Product Code: MRR-742BD517AD07

The Angina Pectoris Drugs Market was valued at USD 1.14 billion in 2023, expected to reach USD 1.20 billion in 2024, and is projected to grow at a CAGR of 5.39%, to USD 1.65 billion by 2030.

The scope of angina pectoris drugs encompasses the treatment and management of symptoms associated with chest pain resulting from insufficient blood flow to the heart. This category includes medications like nitrates, beta-blockers, calcium channel blockers, and antiplatelet agents, which are crucial for alleviating angina symptoms and preventing heart attacks. The necessity of these drugs is underscored by the global prevalence of cardiovascular diseases and the rising geriatric population, making them indispensable in chronic care management. Their applications extend beyond symptom relief; they're integral in improving patient quality of life and reducing the incidence of major cardiovascular events. Primary end-use markets include hospitals, clinics, and retail pharmacies, with expanding reach in developing regions due to increasing health infrastructure and awareness.

KEY MARKET STATISTICS
Base Year [2023] USD 1.14 billion
Estimated Year [2024] USD 1.20 billion
Forecast Year [2030] USD 1.65 billion
CAGR (%) 5.39%

Market growth is predominantly influenced by advancements in drug development and personalized medicine, alongside increasing healthcare expenditures. Emerging opportunities lie in the development of novel therapeutics targeting specific pathways involved in coronary artery disease, driven by ongoing research and technological innovations in pharmaceuticals. An increasing focus on preventive care and lifestyle modifications presents further opportunities for market penetration. However, growth is tempered by stringent regulatory environments, high costs of novel drug development, and potential side effects leading to patient non-compliance.

Key challenges include the competition from generics due to patent expirations and the need to balance efficacy with affordability in low-income markets. Innovation can flourish in areas such as gene therapy, development of combination drugs, and leveraging artificial intelligence to better predict patient responses and optimize drug formulations. Understanding complex patient needs and investing in R&D can lead to breakthroughs. A proactive approach to market expansion through strategic partnerships and rural market penetration can enhance accessibility. The angina pectoris drugs market is dynamic, with significant potential for growth driven by clinical innovation, yet it requires navigating through regulatory and economic challenges to fully realize these prospects.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Angina Pectoris Drugs Market

The Angina Pectoris Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing burden of lifestyle diseases couple with rise in cases of heart related disorders
    • Augmentation of novel drug delivery systems
    • Government suppport in strengthening the prevention and control of cardiovascular disease
  • Market Restraints
    • Concerns regarding side effects associated with certain drug classes
  • Market Opportunities
    • Technological advancements towards personalized cardiovascular medicine
    • Proliferation in the number of drug approvals and clinical research
  • Market Challenges
    • Dearth of skilled and experienced professionals

Porter's Five Forces: A Strategic Tool for Navigating the Angina Pectoris Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Angina Pectoris Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Angina Pectoris Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Angina Pectoris Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Angina Pectoris Drugs Market

A detailed market share analysis in the Angina Pectoris Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Angina Pectoris Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Angina Pectoris Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Angina Pectoris Drugs Market

A strategic analysis of the Angina Pectoris Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Angina Pectoris Drugs Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Limited, Alkem Laboratories Ltd., Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Centurion Remedies Private Limited, Dr. Reddy's Laboratories, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline PLC, Intas Pharmaceuticals Ltd., Ipca Laboratories Ltd., Lupin Ltd., Macleods Pharmaceuticals Pvt Ltd., Mankind Pharma, Merck & Co. Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi-Aventis Groupe S.A., Sumitomo Corporation, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Torrent Pharmaceuticals Ltd..

Market Segmentation & Coverage

This research report categorizes the Angina Pectoris Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Prinzmetal Angina, Stable Angina, and Unstable Angina.
  • Based on Drugs, market is studied across Anti-Ischemic Agents, Antihypertensive Agents, Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Nitrates, and Statins.
  • Based on Route of Administration, market is studied across Oral, Parenteral, and Transdermal.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on End-Users, market is studied across Homecare, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing burden of lifestyle diseases couple with rise in cases of heart related disorders
      • 5.1.1.2. Augmentation of novel drug delivery systems
      • 5.1.1.3. Government suppport in strengthening the prevention and control of cardiovascular disease
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns regarding side effects associated with certain drug classes
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements towards personalized cardiovascular medicine
      • 5.1.3.2. Proliferation in the number of drug approvals and clinical research
    • 5.1.4. Challenges
      • 5.1.4.1. Dearth of skilled and experienced professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Angina Pectoris Drugs Market, by Type

  • 6.1. Introduction
  • 6.2. Prinzmetal Angina
  • 6.3. Stable Angina
  • 6.4. Unstable Angina

7. Angina Pectoris Drugs Market, by Drugs

  • 7.1. Introduction
  • 7.2. Anti-Ischemic Agents
  • 7.3. Antihypertensive Agents
  • 7.4. Antiplatelet Agents
  • 7.5. Beta-Adrenergic Blocking Agents
  • 7.6. Calcium Channel Blockers
  • 7.7. Nitrates
  • 7.8. Statins

8. Angina Pectoris Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral
  • 8.4. Transdermal

9. Angina Pectoris Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Online Pharmacy
  • 9.4. Retail Pharmacy

10. Angina Pectoris Drugs Market, by End-Users

  • 10.1. Introduction
  • 10.2. Homecare
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Americas Angina Pectoris Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Angina Pectoris Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Angina Pectoris Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alembic Pharmaceuticals Limited
  • 2. Alkem Laboratories Ltd.
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca PLC
  • 5. Bausch Health Companies Inc.
  • 6. Bayer AG
  • 7. Centurion Remedies Private Limited
  • 8. Dr. Reddy's Laboratories
  • 9. Eli Lilly and Company
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline PLC
  • 12. Intas Pharmaceuticals Ltd.
  • 13. Ipca Laboratories Ltd.
  • 14. Lupin Ltd.
  • 15. Macleods Pharmaceuticals Pvt Ltd.
  • 16. Mankind Pharma
  • 17. Merck & Co. Inc.
  • 18. Novartis AG
  • 19. Otsuka Pharmaceutical Co., Ltd.
  • 20. Pfizer Inc.
  • 21. Sanofi-Aventis Groupe S.A.
  • 22. Sumitomo Corporation
  • 23. Sun Pharmaceutical Industries Ltd.
  • 24. Teva Pharmaceutical Industries Ltd.
  • 25. Torrent Pharmaceuticals Ltd.

LIST OF FIGURES

  • FIGURE 1. ANGINA PECTORIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANGINA PECTORIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ANGINA PECTORIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ANGINA PECTORIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANGINA PECTORIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANGINA PECTORIS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY PRINZMETAL ANGINA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY STABLE ANGINA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY UNSTABLE ANGINA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ANTI-ISCHEMIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ANTIHYPERTENSIVE AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY BETA-ADRENERGIC BLOCKING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY NITRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANGINA PECTORIS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES ANGINA PECTORIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM ANGINA PECTORIS DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM ANGINA PECTORIS DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM ANGINA PECTORIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM ANGINA PECTORIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM ANGINA PECTORIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 240. ANGINA PECTORIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 241. ANGINA PECTORIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023